Home
Jørn Skavland, PhD immunologi's picture

Jørn Skavland, PhD immunologi

Senior Engineer
  • E-mailJorn.Skavland@uib.no
  • Phone+47 55 58 53 36
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen

My research projects are focused on understanding cellular signaling (phosphorylation) and can be divided in four topics.

-          Basal research understanding signaling node cascade.

-          Aberrant signaling pattern in chronic and acute myeloid leukemia.

-          Phospho-signaling and hematologic pattern to immunologic response.

-          Mass Cytometry – a new instrument analyzing over 40 parameters in a single cell manner.                      

I have shown that analyzing in vivo patient whole blood, the change in the signaling pattern shortly after start a new treatment regime reflects the drug that is given. Using this methodology I’m involved in several cancer sub-studies - local and international.

 

Monitoring signaling patterns in patients starting a new treatment is likely to be of important for patient progress, early drug evaluation, as well as increased understanding of complex diseases. 

Academic article
  • Show author(s) (2021). Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers. 1-18.
  • Show author(s) (2020). A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. Journal of Biological Chemistry. 15 pages.
  • Show author(s) (2019). Whole blood preservation methods alter chemokine receptor detection in mass cytometry experiments. JIM - Journal of Immunological Methods.
  • Show author(s) (2019). Titrating complex mass cytometry panels. Cytometry Part A. 1-6.
  • Show author(s) (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Show author(s) (2018). Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case reports in hematology.
  • Show author(s) (2017). Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 1361-1367.
  • Show author(s) (2016). Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 216-227.
  • Show author(s) (2015). Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
  • Show author(s) (2013). Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease.
  • Show author(s) (2012). In vitro screening for putative psoriasis-specific antigens among wheat proteins and peptides. British Journal of Dermatology. 67-73.
  • Show author(s) (2012). Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
  • Show author(s) (2011). Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal.
  • Show author(s) (2010). Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 574-583.
  • Show author(s) (2010). Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology.
  • Show author(s) (2010). Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 4547-4556.
  • Show author(s) (2009). Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer.
  • Show author(s) (2007). Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 2589-2596.
  • Show author(s) (2007). Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 13-24.
Academic lecture
  • Show author(s) (2019). Comprehensive characterization and kinetics of circulating lymphocytes in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
Doctoral dissertation
  • Show author(s) (2013). Risk stratification and therapy response monitoring by phosphoprotein profiles in acute myeloid leukaemia.
Abstract
  • Show author(s) (2010). Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 510-510.
  • Show author(s) (2008). Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
Poster
  • Show author(s) (2018). Comprehensive characterization of circulating T follicular helper cells and plasmablasts in human volunteers experimentally infected with enterotoxigenic Escherichia coli.
Academic literature review
  • Show author(s) (2016). Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 579-589.
  • Show author(s) (2011). Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 269-281.
Article in business/trade/industry journal
  • Show author(s) (2014). Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. Journal of Clinical Medicine.

More information in national current research information system (CRIStin)